STADA Arzneimittel AG, one of Germany’s longest-standing pharmaceutical companies, has appointed Tomas Mihal to the position of Head of Germany and Global Executive Committee member with effect from November 1, 2025. The leadership transition is a momentous one for STADA, as the group tightens its focus on innovation, healthcare access, and sustainable growth in its largest and most competitive market.

A Strategic Appointment for a Key Market

This appointment is both a strategic and symbolic move, with Germany accounting for a substantial share of STADA’s global revenue. Headquartered in Bad Vilbel near Frankfurt, the company has grown fast across Europe and beyond-but its home market remains the cornerstone of its operations.

Tomas Mihal, 45, comes with more than twenty years of experience in the pharmaceutical and healthcare business, with senior leadership roles spanning Central and Eastern Europe. He is highly regarded for his strong commercial acumen and forward-thinking leadership. Mihal has built a track record of delivering market share through patient-centric innovation and operational discipline.

“Germany represents both a legacy and a future opportunity for STADA,” Mihal said upon his appointment. “Our goal is to combine our long-standing trust with patients and partners with an innovative mindset that ensures accessible healthcare solutions for all.”

Driving Growth Through a Diversified Portfolio

STADA’s business model rests on three pillars: generics, consumer healthcare, and specialty pharmaceuticals. Over the last years, each one has grown substantially, positioning STADA as a significant European player that competes against Teva, Sandoz, and Viatris.

Under Mihal’s leadership, the company will seek to accelerate the growth of its consumer healthcare portfolio, which includes OTC brands, wellness products, and preventive health solutions. This segment has seen growing demand with German consumers increasingly prioritizing holistic and self-directed health management.

Meanwhile, STADA continued to invest heavily in biosimilars and specialty medicines, targeting key indications such as oncology, neurology, and rare diseases. Mihal’s experience managing complex pharmaceutical portfolios across diverse markets positions him well to navigate Germany’s highly regulated and competitive healthcare landscape.

Balancing Affordability with Innovation

“Caring for People’s Health as a Trusted Partner” remains the guiding principle of STADA’s strategy. But leaders such as Mihal face the challenge of a balance between affordability and the push toward innovation. The German healthcare system is characterized by tight price controls and very strict reimbursement frameworks, in which it is often hardly possible for pharma companies to pursue innovation with prices that remain accessible.

Mihal will lead the expansion of partnerships with health insurers, pharmacies, and government stakeholders so that patients can continue to access STADA’s generics and biosimilars at an affordable level without compromising quality. He will also lead efforts in modernizing distribution and increasing digital engagement with patients and professionals.

Mihal emphasized digital transformation in the pharmaceutical industry in his first statement as country head: “Digital tools, AI-driven insights, and real-time supply chain visibility are the new dimensions of how we deliver care. STADA Germany will continue to invest in these areas toward better efficiency and responsiveness for patients and partners alike.”

Expanding the Culture of Innovation and Responsibility

Beyond business performance, STADA has been actively building a culture of sustainability and social responsibility. Under CEO Peter Goldschmidt, the company has integrated ESG-particularly focused on reducing carbon emissions, improving workplace inclusion, and ensuring ethical sourcing throughout its supply chain-into the core of the company’s operations.

Mihal’s leadership is expected to reinforce these commitments at the national level. STADA Germany will continue to champion green manufacturing practices, optimize packaging sustainability, and support community health initiatives. The company’s “Healthier Together” campaign, launched recently, seeks preventive health awareness for families and senior citizens and remains at the core of its local outreach.

Navigating an increasingly competitive and evolving landscape

Worth over €50 billion, the German pharmaceutical market is one of the most developed in Europe; it is simultaneously one of the most fiercely competitive. In a scenario of continuously rising healthcare costs, aging demographics, and growing regulatory pressure, pharmaceutical companies are always under tight pressure to innovate more efficiently.

Mihal’s appointment is a signal of STADA’s confidence in facing such challenges with agility and collaboration. His pragmatic management style, combined with regional experience, will help STADA maintain its reputation as a trustworthy, innovation-driven healthcare partner while seizing new opportunities in emerging therapeutic areas.

Looking Ahead With Tomas Mihal at the helm, STADA is about continuity and renewal as it gears up for the next phase of its expansion. The company remains committed to its mission of making high-quality medicines accessible while evolving into a more modern, tech-enabled, and sustainability-focused healthcare player. For Germany – a market right at the heart of the global pharmaceutical transformation – this change in leadership is much more than an internal transition. It is a signal that STADA wants to play a leading role in shaping the future of European healthcare, in which patient trust, innovation, and responsibility must go hand in hand.